This is due to the gastric emptying delaying effect of short-acting agents, and the gastric emptying delaying effect of long-acting agents gradually decreases due to tachyphylaxis, thereby reducing the effect of postprandial glycemic control
Available from: Bertoccini L, Baroni MG (2021) GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
Some researchers report that injecting on a completely empty stomach intensifies initial nausea
The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
Now, lets address the key question: Which semaglutide has the least side effects
